KRAS and neoplasm: Further studies have revealed that FASN inhibitors could accelerate the ROS-and iron-dependent cell death, depletion of lipid droplets, and inhibit de novo lipogenesis, causing FA synthesis-dependent cell death in KRAS-positive tumor cells [94, 96].